Wells Fargo & Company MN cut its holdings in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 71.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 211,326 shares of the life sciences company’s stock after selling 538,906 shares during the period. Wells Fargo & Company MN owned 0.25% of Integra Lifesciences worth $13,920,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in Integra Lifesciences in the 2nd quarter worth approximately $538,000. Paloma Partners Management Co purchased a new position in Integra Lifesciences in the 2nd quarter worth approximately $12,012,000. Bank of Montreal Can lifted its holdings in Integra Lifesciences by 55.8% in the 2nd quarter. Bank of Montreal Can now owns 16,018 shares of the life sciences company’s stock worth $1,031,000 after purchasing an additional 5,739 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in Integra Lifesciences by 52.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 44,336 shares of the life sciences company’s stock worth $2,856,000 after purchasing an additional 15,286 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in Integra Lifesciences by 12.1% in the 2nd quarter. Sei Investments Co. now owns 179,756 shares of the life sciences company’s stock worth $11,578,000 after purchasing an additional 19,377 shares in the last quarter. 85.94% of the stock is currently owned by institutional investors.
A number of research analysts recently commented on the company. Oppenheimer reissued a “buy” rating and issued a $70.00 price target on shares of Integra Lifesciences in a report on Wednesday, October 31st. JMP Securities lowered their price target on Integra Lifesciences from $66.00 to $62.00 and set a “market outperform” rating on the stock in a report on Friday, November 2nd. UBS Group assumed coverage on Integra Lifesciences in a report on Tuesday, November 27th. They issued a “neutral” rating and a $58.00 price target on the stock. Zacks Investment Research downgraded Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 25th. Finally, Citigroup reduced their price objective on Integra Lifesciences from $66.00 to $60.00 and set a “neutral” rating on the stock in a research note on Friday, November 2nd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $61.62.
NASDAQ:IART opened at $49.96 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.08 and a current ratio of 3.20. Integra Lifesciences Holdings Corp has a 1 year low of $45.96 and a 1 year high of $67.50. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 21.16, a PEG ratio of 1.59 and a beta of 0.76.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.59. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The business had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. During the same quarter in the previous year, the company posted $0.45 EPS. The company’s revenue was up 31.2% compared to the same quarter last year. On average, equities analysts expect that Integra Lifesciences Holdings Corp will post 2.39 earnings per share for the current fiscal year.
In related news, Director Barbara B. Hill bought 3,705 shares of the business’s stock in a transaction dated Monday, November 5th. The shares were purchased at an average price of $53.90 per share, with a total value of $199,699.50. Following the transaction, the director now owns 63,381 shares in the company, valued at approximately $3,416,235.90. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of the business’s stock in a transaction that occurred on Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total value of $2,949,456.44. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at approximately $8,475,927.46. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Story: When is a capital gain realized?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.